Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 2548 results for methods

  1. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210

    Technology appraisal guidance
    Discontinued

  2. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. What is the clinical and cost effectiveness of cognitive behavioural therapy (CBT) for adults with tinnitus delivered by appropriately trained healthcare professionals other than psychologists (for example, audiologists)?

    view that these expensive interventions should only be used when other methods (digital CBT and group-based interventions) have been...

    Research recommendation
    Published
    17 March 2020

  4. What is the clinical and cost effectiveness of psychological therapies for children and young people who have tinnitus-related distress?

    view that these expensive interventions should only be used when other methods (digital CBT and group-based interventions) have been...

    Research recommendation
    Published
    17 March 2020

  5. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development Reference number: GID-TA10589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  8. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued Reference number: GID-TAG363

    Technology appraisal guidance
    Discontinued

  9. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  10. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  11. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

    Technology appraisal guidance
    Discontinued

  12. Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

    Discontinued Reference number: GID-TA10210

    Technology appraisal guidance
    Discontinued

  13. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued Reference number: GID-TAG411

    Technology appraisal guidance
    Discontinued

  14. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development Reference number: GID-TA10598 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Kidney transplantation (rejection) - everolimus [ID117]

    Discontinued Reference number: GID-TAG241

    Technology appraisal guidance
    Discontinued